SBIR/STTR Research Award

Identification of Natural Mesenchymal Stem Cell Ligands

Award identifier 5f8bc5f5556e0c44016d8f83d2136dff1435117f163a0c62f461e2940abf6c61Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$192,844

Program and phase

SBIR · Phase I

Award year

2003

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
SELECTIVE GENETICS, INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
Not reported
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): Adult stem cells from bone marrow have the potential to provide a vast resource for regenerative medicine which would allow the replacement of injured or defective cells and tissues. While it is known that mesenchymal stem cell (MSC) populations from bone marrow have the potential to differentiate into many different cell types including bone, cartilage, fat and possibly others, there is little understanding of the molecular basis that characterizes the different progenitor cells. Also lacking is a clear understanding of the factors that regulate their growth and differentiation. The purpose of this grant proposal is to identify and characterize natural ligands from within the human genome that target cell surface receptors on mesenchymal stem cells. Phage display libraries will be constructed using novel cDNA display methods and selected on MSCs to identify natural peptide ligands that bind and internalize into MSCs. Novel selection methods will be used to select internalizing ligands with greater sensitivity than currently available techniques. Selected ligands will be characterized for specificity and function. Near term, these ligands will serve as targeting ligands for the introduction of genes and drugs into mesenchymal stem cells that would augment their use in tissue engineering and treatment of disease. Moreover, it is likely that certain ligands will be useful as biological drugs that can be used commercially to either maintain stem cell populations in an undifferentiated state, or to stimulate their differentiation to specific cell types. In the long term, an understanding of these natural ligands and their receptors on bone marrow stem cells will allow rational design of drug treatments that augment the bodies own mechanism for tissue repair due to injury (i.e. wound healing, bone and cartilage growth), or due to cell loss from diseases like diabetes, Parkinson's disease, and muscular dystrophy.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.